Clarus Therapeutics Holdings

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company was founded in 2004 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blue Water Acquisition Corp.

Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021

Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies

News for Clarus Therapeutics Holdings Stock (CRXT)